Dana-Farber Cancer Institute: Head and Neck Neoplasms trials

The registry lists 25 Head and Neck Neoplasms studies with Dana-Farber Cancer Institute as lead sponsor. 5 are open to participants now and 8 have results posted.

Phase 1 9Phase 2 15Phase 3 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clonal Hematopoiesis Chemotherapy and Radiation Effects StudyRecruitingNCT07675967
• Toripalimab With Chemotherapy for Sinus CancerRecruitingNCT06940180Phase 2
• PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCCRecruitingNCT06239220Phase 2
• Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCCRecruitingNCT05726370Phase 2
• Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell CarcinomaRecruitingNCT03875716Not applicable
• Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal CancerCompletedNCT03894891Phase 2Results posted
• Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHNActive, not recruitingNCT03085719Phase 2Results posted
• Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral CavityActive, not recruitingNCT02919683Phase 2Results posted
• Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal CancerCompletedNCT02865135Phase 1/2Results posted
• Image-guided Cryoablation of Head, Neck and Spine TumorsCompletedNCT02085941Not applicableResults posted
• Ponatinib for Squamous Cell Lung and Head and Neck CancersTerminatedNCT01761747Phase 2/3Results posted
• Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and NeckTerminatedNCT00570674Phase 1/2Results posted
• Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)CompletedNCT00095875Phase 3Results posted
• Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid TumorsSuspendedNCT03065062Phase 1
• Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and NeckActive, not recruitingNCT02474368Phase 1
• RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck CancerTerminatedNCT01058408Phase 1
• C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT00402545Phase 1
• Randomized Amifostine For SCCHNCompletedNCT00095927Phase 2
• Capecitabine For Nasopharyngeal CancerCompletedNCT00095901Phase 2
• Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck DysplasiaCompletedNCT00052611Phase 2
• Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck CancerCompletedNCT00006107Phase 1
• Combination Chemotherapy in Treating Patients With Stage IIB, Stage III, or Stage IV Cancer of the NasopharynxStatus unknownNCT00004164Phase 2
• Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck CancerCompletedNCT00004070Phase 1/2
• High-dose ICE With AmifostineCompletedNCT00003657Phase 2
• Chemotherapy Plus Radiation Therapy in Treating Patients With Squamous Cell Cancer of the Head and NeckCompletedNCT00003200Phase 1